What is Qcdx?
Qcdx is a medical device company dedicated to the early detection of circulating tumor cells (CTCs) for precise cancer diagnoses. Their proprietary technology enables enrichment-free profiling and isolation of rare CTCs, providing real-time cancer intelligence via minimally invasive blood tests. The company's solutions are designed to optimize treatment strategies, monitor therapeutic efficacy, and assess treatment toxicity, ultimately aiming to enhance patient outcomes and quality of life. Qcdx serves oncologists and the pharmaceutical industry, supporting critical cancer research and drug discovery initiatives across all disease stages.
How much funding has Qcdx raised?
Qcdx has raised a total of $7M across 2 funding rounds:
Debt
$14K
Other Financing Round
$7M
Debt (2021): $14K with participation from PPP
Other Financing Round (2025): $7M, investors not publicly disclosed
Key Investors in Qcdx
PPP
Public-Private Partnership
What's next for Qcdx?
With the recent major strategic investment and substantial enterprise-level backing, Qcdx is poised for accelerated growth and market expansion. This capital is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the commercialization of their advanced CTC detection technology. The company's focus on precision diagnostics and real-time cancer intelligence positions it as a key player in the evolving landscape of oncology, with potential to significantly impact cancer care pathways and drug development.
See full Qcdx company page
